Abstract
The long-term safety, tolerability, and antihypertensive effects of irbesartan/hydrochlorothiazide (HCTZ) were assessed in hypertensive patients (seated diastolic blood pressure [SeDBP] 95–110 mm Hg). Patients (n = 1098) completing two randomised, double-blind trials of irbesartan alone, HCTZ alone, irbesartan/HCTZ combinations, or placebo, took 1 year of open-label therapy starting with irbesartan 75 mg/HCTZ 12.5 mg once daily. If target blood pressure (BP) (<140/<90 mm hg) was not achieved, the dose was titrated sequentially at 2- to 4-week intervals to irbesartan 150 mg/hctz 12.5 mg, then to irbesartan 300 mg/hctz 25 mg. if necessary, adjunctive therapies were added. mean changes in trough seated systolic bp/sedbp at months 2, 6, and 12 were −19.1/−14.2 mm hg (n = 941), −20.7/ −15.7 mm Hg (n = 948), and −20.6/−15.6 mm Hg (n = 898), respectively. From months 2 to 12, normalisation rates (trough SeDBP <90 mm hg) ranged from 75–85% and total responder rates (normalised or ⩾10 mm hg trough sedbp reduction) ranged from 81–91%, while target bp was achieved in 65–75% of patients. at all time-points, most patients (⩾87%) were receiving irbesartan/hctz alone. eighty-two patients (7.5%) discontinued the study due to adverse events, with half of these events considered unrelated to study medication. there were no reports of serious adverse events related to study medication. long-term therapy with irbesartan/hctz is safe, well tolerated, and maintains normalised bp in >80% of patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Raskin, P., Guthrie, R., Flack, J. et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 13, 683–687 (1999). https://doi.org/10.1038/sj.jhh.1000888
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000888
Keywords
This article is cited by
-
Optimizing hypertension management in clinical practice
Journal of Human Hypertension (2006)
-
Angiotensin receptor blockade in the challenging era of systolic hypertension
Journal of Human Hypertension (2004)